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Abstract
New pandemics are a serious threat to the health of the entire world. They are essentially of viral
origin and spread at large speed. A meeting on this topic was held in Lyon, France, within the XIXth
Jacques Cartier Symposia, a series of France-Québec meetings held every year. New findings on
HIV and AIDS, on HCV and chronic hepatitis, and an update on influenza virus and flu were covered
during this meeting on December 4 and 5, 2006. Aspects of viral structure, virus-host interactions,
antiviral defenses, drugs and vaccinations, and epidemiological aspects were discussed for HIV and
HCV. Old and recent data on the flu epidemics ended this meeting.
Background
The XIXth Jacques Cartier Symposium was held to discuss
recent advances on new viral pathogens that are rapidly
expanding such as the human immunodeficiency virus
(HIV-1) causing AIDS, the hepatitis C virus (HCV), caus-
ing chronic hepatitis and hepatocellular carcinoma, and
influenza virus causing flu. These viral infections all have
important human, social and political consequences
worldwide. The opening lecture by the director of the
French national agency against AIDS and hepatitis was
followed by a session on the structural biology of HIV and
HCV and the biochemistry of essential viral components.
In the second session, aspects of virus-host relationships
were discussed and the third one tackled problems of
innate immunity, anti-viral defenses and counteractions.
Session 4 dealt with anti-viral drugs and vaccination and
session 5 evoked epidemiological aspects of HIV and HCV
transmission. Finally, an update on the previous and
pending flu epidemics ended the meeting.
In his opening lecture Jean-François Delfraissy, the new
director of the Agence Nationale de Recherches sur le
SIDA et les hépatites (ANRS, Paris, France), gave a brief
outline of the major tasks of ANRS, namely the support of
fundamental research on HIV and HCV/HBV, based on
excellency. JF Delfraissy also summarized the agency
major efforts in the growing field of anti-HIV vaccination
and prevention including education, training and circum-
cision. He cited ongoing and published studies on effec-
tiveness and safety of genotyping, the ART-LINC cohort
the TRIVACAN assay, HIV and tuberculosis ongoing with
the National Institutes of Health, USA, the circumcision
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infected individuals, and therapeutic assays on HIV/HCV
coinfection [1-5].
Structural biology and biochemistry of HIV and HCV
In this session, Elena Chertova (Frederick NCI/NIH,
USA) presented outstanding data on the characterization
of trimeric envelope structures on the surface of HIV-1
and SIV virions. Biochemical analyses, electron tomogra-
phy and image processing support an overall virion struc-
ture where about 8–9 ENV trimers are found on a HIV-1
virion and 70–79 on the average on mutant SIV known to
contain a high level of the viral envelope [6-8]. These ENV
trimer counts combined with biochemical analyses allow
calculation of the number of gag molecules per virion,
yielding a value of approximately 1400. These results
demonstrate the presence of envelope trimers on the vir-
ion surface, and have important implications for under-
standing virion formation, virus-cell interactions, and
virus neutralization.
Because the genome of HIV, HCV and influenzae viruses
is made of RNA, the talk given by Renée Schröeder (Uni-
versity of Vienna, Austria) addressed the major issue on
how RNA molecules can adopt a functionally relevant
conformation, amongst billions of possible structures,
necessary for their expression and their replication. A
number of RNA cofactors have been discovered, which
include specific nucleic acids binding proteins, chaper-
ones and helicases [9-11]. In that respect, RNA chaper-
ones appear to be wide spread in nature, where they help
RNA molecules rapidly reach their functional conforma-
tion, in physiological conditions and in the absence of
ATP.
To pursue on this theme of viral RNA conformation, Jean-
Luc Darlix (INSERM, École Normale Supérieure, Lyon,
France) summarized a decade of research dedicated to the
nucleocapsid protein NC of HIV-1. In fact, NC is both a
specific nucleic acid binding protein and a potent RNA
chaperone that guides reverse transcriptase (RT) during
proviral DNA synthesis, and selects and dimerizes the
genomic RNA during virus assembly (see also talk of Del-
phine Muriaux) [12-15]. JL Darlix also presented recent
data showing that NC can control the level of nucleotide
misincorporation during cDNA synthesis by RT, via spe-
cific NC-RT-cDNA interactions allowing RT-mediated
nucleotide excision-repair.
To continue on the NC protein of HIV-1, Yves Mély
(CNRS, Faculté de Pharmacie, Strasbourg) gave an over-
view on the 3D structure of NC highlighting the fact that
this small viral protein, formed of two zinc fingers flanked
by basic residues, operates through an hydrophobic pla-
teau. Mutating this plateau results in the production of
non-infectious viruses. A chemical class of anti-NC agents
have been selected that specifically interact with the NC
plateau. As illustrated by Y. Mély, some of these agents
were found to completely inhibit the chaperoning func-
tion of NC [16,17].
HCV has come a long way since its discovery in 1989 with
the recent establishement of a cell culture system to inves-
tigate its replication and biogenesis [18]. In the mean
time, several surrogate models have been developed to
study some steps of HCV life cycle. Virus-like particles
(VLPs) obtained by expressing the genes encoding HCV
structural proteins in mammalian cells have been used as
a model for investigating HCV morphogenesis. Philippe
Roingeard (INSERM, Université de Tours, France)
reported recent data on the morphogenesis of HCV VLPs
at the level of the endoplasmic reticulum (ER) membrane,
describing HCV core protein domains required or dispen-
sable for this phenomenon [19]. Results also indicate that
the processing of the HCV core protein by the signal pep-
tide peptidase is required for HCV VLP assembly [20].
As well documented for HIV-1, HCV also shows remarka-
ble sequence variability due to the lack of a proofreading
activity of the HCV RNA-dependent RNA polymerase. The
HCV dedicated databases such as the European Hepatitis
C Virus Database (euHCVdb) [21,22] allow the investiga-
tion of the genetic and structural variability of all available
HCV sequences as presented by François Penin (CNRS,
IBCP, Lyon, France). Despite the high degree of variabil-
ity, amino acid sequence analyses reveal a global conser-
vation of protein structures. Interestingly, the
conservation of some amino acids in membrane protein
domains is likely related to their essential role in the for-
mation of the RNA replication complex, which is associ-
ated with membranes [23]. The hydrophilic amino acids
generally located at the protein surface are the most varia-
ble, offering a high potential to modulate interactions
with host components, and thus a better replicative fitness
of the variants.
Virus-host relationships
Because viruses such as HIV, HCV and Influenzae are par-
asites, virus-cell interactions are required at all steps of the
virus replication cycle. Specific molecular events between
viral and cellular components mediate viral entry, traffick-
ing, expression and release [24]. Some aspects of these
virus-host relationships have been addressed. HIV-1 entry
into the target cell involves the formation of a trimolecu-
lar complex consisting of SUgp120, a CD4 receptor and a
chemokine co-receptor. Michel J. Tremblay (CHUL, Uni-
versité Laval, Québec, Canada) discussed interactions
between cell-derived components incorporated into viri-
ons and their natural counter-receptors for their contribu-
tion to HIV-1 entry/infection. He showed that thePage 2 of 9
(page number not for citation purposes)
Retrovirology 2007, 4:8 http://www.retrovirology.com/content/4/1/8presence of host-derived ICAM-1 on virions results in a 5
to 10 fold increase in virus infectivity on target T-cells and
nearly 100 folds when they infect activated T cells express-
ing LFA-1. Virus entry studies including subcellular frac-
tionation experiments with CD4+ T cells demonstrated
that the acquisition of ICAM-1 by nascent HIV-1 modified
the entry route of the virus, more likely to release their
material within the cell cytosol instead of being endocy-
tosed. Activation of CD4+ T cells resulted in LFA-1 cluster-
ing, promoting the early events of HIV-1 replication
through an interaction between virus-embedded host
ICAM-1 and LFA-1 clusters. HIV-1 is concentrated in
microdomains rich in LFA-1 clusters [25,26].
HIV-1 expression is controlled by the viral trans-activator
Tat. Recently, RNA interference (RNAi) appeared to be a
major pathway of gene regulation both by exogenous
small interfering (si) RNAs and by endogenous viral or
cellular micro (mi) RNAs. Kuan-Teh Jeang (NIAID, NIH,
Bethesda, USA) spoke on several topics related to Tat and
miRNAs. First, he presented new data addressing the pos-
sibility that Tat is a virion-associated protein since he has
previously suggested that Tat might be in virions [27].
Next, he touched upon how HIV-1 infection, perhaps
through Tat-Dicer interaction [28,29], alters the expres-
sion profile of miRNAs in human cells [30]. He com-
mented on different miRNA signatures in PBMCs from
groups of AIDS patients at various stages of disease pro-
gression. Finally, KT Jeang reported that the HIV-1 PBS-
tRNA structure could be a Dicer-processed substrate in
infected cells.
Viruses use the translation cellular machinery to synthe-
size their proteins. Théophile Ohlmann (INSERM-ENS,
Lyon, France) showed that retroviruses have developed
structural features and strategies that enable them to take
over from the cellular translation machinery. Lentiviruses
HIV-1, HIV-2, FIV and SIV have been shown to initiate
translation by Internal Ribosome Entry Segments (IRES).
These IRESes have been mapped in the 5'UTR and in the
gag coding region and play an important role in the con-
trol of viral protein synthesis. He showed that IRES from
HIV-2 is of a novel type. In HIV-2, 3 AUG start codons ini-
tiate the synthesis of 3 gag isoforms and leaderless trans-
lation is very efficient showing the role of the IRES. In
addition the translation initiation factor eIF4G can be
cleaved by HIV-1 and HIV-2 proteases, which modifies the
AUG selection on its cognate RNA and has a different
impact on both cellular and viral translation. Finally, the
binding of the Gag polyprotein to the 5' leader has an
important impact on the modulation of viral protein syn-
thesis [31].
Viral translation and consequently viral replication is also
influenced by cellular factors. Anne Gatignol (Lady Davis
Institute, McGill University, Montréal, Canada) talked
about the cellular response to HIV infection mediated by
PKR and RNAi and its control by the cellular TAR RNA
binding protein (TRBP). She showed that PKR is not acti-
vated in HIV-infected lymphocytes, but is activated in
HIV-infected astrocytes that do not replicate the virus effi-
ciently. This difference in cell response is due to the low
amount of TRBP in astrocytes that cannot counteract PKR
activation [32,33]. TRBP is a cellular protein that inhibits
PKR activation directly and by controlling the activity of
the PKR activator PACT. Evidence on the control of PACT
by TRBP was presented. TRBP is part of the RNA-induced
silencing complex (RISC) that mediates RNAi [34]. It has
been suggested that RNAi could be part of the cellular
response to viral infection in mammals like in plants and
lower eukaryotes. However, TRBP being part of the RISC
and favoring HIV replication raises the question of
whether HIV diverts a cellular pathway or evades from
antiviral immunity [35]. She discussed the effects of TRBP
or Dicer inhibition on HIV production and the activity of
HIV on RNAi.
HIV-1 assembly
The HIV-1 structural Gag polyprotein is responsible for
orchestrating the assembly process and alone is sufficient
for the production of viral particles. Numerous recent
studies have shown that HIV-1 Gag assembly could take
place at the plasma membrane (PM) or/and in late endo-
somal/multivesicular compartments (LE/MVB) depend-
ing on the cell type, thus raising the possibility that LE/
MVB may represent early intermediates where HIV-1
assembly is initiated [36,37]. Delphine Muriaux
(INSERM-École Normale Supérieure, Lyon, France) dis-
cussed the intracellular trafficking and assembly of Gag
and the role of Gag-RNA interactions in these processes.
Using immunofluorescence/FISH coupled to confocal
microscopy, sub-cellular fractionation and RT-PCR tech-
niques, she showed that in the case of wild-type HIV-1
virus, Gag-mediated assembly and budding occur both at
the PM and on intracellular endosomal membranes [38].
In the case of NC mutants, in which NC-RNA interactions
are impaired [39,40], she found that NC-mutated Gag dis-
played decreased particle release and strongly accumu-
lated at the PM. On the basis of these results, she favors
the view that HIV-1 can assemble both at the PM and on
LE/MVB membranes with the requirement of NC-RNA
interactions for Gag assembly and trafficking.
Éric A. Cohen (IRCM, Université de Montréal, Montréal,
Canada) addressed similar issues and presented an analy-
sis of Gag trafficking in 293T cells where Gag localizes
both at the PM and LE/MVB at steady-state. Using an
approach that combined pulse chase-labeling and subcel-
lular fractionation, he provided evidence indicating that
the PM is the primary site of productive HIV-1 particlePage 3 of 9
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detected in LE/MVB were shown to result from an inter-
nalization process from the PM towards MVB. Next, he
touched on host cell factors that might regulate the steady-
state accumulation of Gag and mature virions in different
cell types. He reported that expression of MHC-II mole-
cules (HLA-DR), which was previously shown to induce a
relocation of Gag and mature particles to LE/MVB [41]
enhanced Gag and mature particle internalization from
the PM.
HCV biology
Recently, a cell-culture system that allows a relatively effi-
cient amplification of HCV (HCVcc) has been reported.
This system is based on the transfection of Huh-7 cells
with genomic HCV RNA of the genotype 2a JFH1 strain
cloned from an individual with fulminant hepatitis [18].
As presented by Jean Dubuisson (CNRS, Institut Pasteur,
Lille, France), the HCVcc system allows for the first time
the study of the complete viral life cycle. Surprisingly, the
envelope glycoproteins are detected in the ER, whereas the
core protein is exclusively found in association with lipid
droplets in cells infected by HCVcc [42]. Another major
tool in the study of HCV has been the development of ret-
rovirus pseudotypes containing HCV envelope glycopro-
teins that have been called HCVpp [43]. The HCVpp and
HCVcc systems begin to reveal some information on HCV
determinants and cellular factors involved in virus entry.
CD81 tetraspanin, scavenger receptor BI and Claudin-1
have been shown to be important cellular entry factors for
HCV. In addition, some lipoproteins or apolipoproteins
can modulate the entry process. Finally, some glycans
present on HCV envelope glycoproteins have been shown
to play a role in virus entry.
Innate immunity, anti-viral defenses and counteractions
Virus entry induces a cell response to the infection.
Aspects of the innate immunity and the role of dendritic
cells in the adaptive immune response against HIV and
HCV were discussed. The mechanisms whereby HCV
evades the host's immune defenses and establishes per-
sistent infection remain elusive. As reported by John His-
cott (Lady Davis Institute, McGill University, Montréal,
Canada) HCV NS3-4A protease has been shown to inter-
fere with double-stranded RNA signaling pathways. It dis-
rupts the cellular RNA helicase retinoic acid-inducible
gene I (RIG-I) pathway through proteolysis of a newly dis-
covered essential adaptor protein of interferon regulatory
factor-3 (IRF-3) activation [44-46]. Due to its recent
simultaneous discovery by four different groups, this
adaptor protein has received four different names: IPS-1,
Cardif, VISA and MAVS. NS3-4A cleavage of MAVS/IPS-1/
VISA/Cardif caused its relocation from the mitochondrial
membrane to the cytosolic fraction. The IKK-related
kinase IKKε that colocalizes with MAVS at the mitocho-
drial membrane is also disrupted by NS3/4A expression.
These data provide the first link between mitochondrial
function, development of innate antiviral response and
HCV evasion mechanisms [47].
A natural innate resistance to HIV-1 occurs in old world
monkeys. Jeremy Luban (Colombia University, USA; IRB,
Bellinzona, Switzerland) reported the discovery of
TRIM5α or TRIM-Cyp as cellular restriction factors that
mediate this resistance [48,49]. TRIM5 specificity in owl
monkeys is conferred by a C-terminal CypA domain that
binds CA of HIV-1, SIV AGM and FIV, or by the CA-spe-
cific C-terminal SPRY domain in other particular primate
species. TRIM5 may be thought of as a cytoplasmic recep-
tor within the innate immune system which recognizes
CA-specific determinants on the retroviral protein core
[50]. Thus far, HIV-1 escape from TRIM-Cyp has not been
observed.
Dendritic cells (DCs) capture pathogens like HIV or HCV
virions and present antigens, activating an adaptive
immune response. A fraction of the captured HIV virions
is transmitted to CD4+ lymphocytes by cell-to-cell transfer
through the formation of virological synapses between
infected and target cells. Olivier Schwartz (Institut Pas-
teur, Paris, France) demonstrated the importance of cell
contacts for HIV-1 transmission by altering cell-to-cell
contact by gentle shaking. Using an assay to assess the rel-
ative contributions of free and cell-associated virions, he
reported that cell-to-cell transfer is the predominant mode
of HIV spread [51]. He next documented how HIV-1
infected lymphocytes poorly conjugated with antigen-pre-
senting cells and form abnormal immunological syn-
apses. TCR and Lck accumulated in the recycling
endosomes in HIV-1 infected lymphocytes, altering the
endocytic and signaling networks at the immunological
synapse and facilitating viral spread [52].
The mechanism whereby HCV evades the host's immune
defenses and establishes persistent infection remain elu-
sive. With the requirement of functional Toll-like receptor
(TLR) signaling pathways for full DC activation and gen-
eration of CD4+ T cell memory responses [53,54], the
presentation of Daniel Lamarre (CHUM, Montréal, Can-
ada) revived the concept that specific HCV-DC interac-
tions exert an inhibitory pressure on innate responses
[55], (Rodrigue-Gervais IG, Jouan L, Beaulé G, Sauvé D,
Bruneau J, Willems B, Sékaly RP, Lamarre D, manuscript
submitted). Analyses of dendritic cells (DC) isolated from
the blood of HCV infected patients showed that the mye-
loid DC subset displays impaired expression of IL-12 and
TNF-α but not IL-6 or CCL3 in response to
poly(I):poly(C) (TLR3 ligand) and LPS (TLR4 ligand). In
addition, attenuation of innate sensing was HCV RNA
density-dependent. Data support the active contributionPage 4 of 9
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ger signal responsiveness of a sub-population of myeloid
DC in vivo, which might contribute to the failure of chron-
ically infected patients to generate and maintain long-
term HCV-specific CD4+ T cell responses.
Anti-viral drugs and vaccination
The current anti-HCV therapy is based on the use of poly-
ethylene glycol modified IFN-α in combination with rib-
avirin. However, this treatment is expensive, relatively
toxic and effective in only half of treated patients. New
therapies are therefore needed. Besides the development
of small anti-protease and anti-polymerase inhibitors,
other approaches like siRNAs targeting HCV sequences
offer potentially new approaches for therapeutic interven-
tion as reported by Chris Richardson (Dalhousie Univer-
sity, Halifax, Canada). Although resistance can be
observed in replicon cell lines in the presence of a single
siRNA, using more than one siRNA targeting different
regions of HCV genome can reduce the appearance of
resistant mutants. A major problem with the siRNA
approach is the delivery of these molecules into the
cytosol. Delivery of these molecules in the form of shRNA
with an adenovirus vector might be a way to circumvent
this problem [56,57].
Geneviève Inschauspé (Transgene, Lyon, France) gave a
talk on 'Hopes and beyond in the development of vac-
cines against hepatitis C virus' based on the view that long
lasting and specific T cell responses correlate with lower-
ing of HCV viremia [58]. Vaccines that have so far reached
the clinics are not tailored to mount such responses. Sec-
ond generation vaccines are being developed with the
help of murine-based surrogate challenge assays provid-
ing for the in vivo testing of vaccine induced T cells. These
assays typically use recombinant vaccinia viruses or listeria
monocytogenes [59]. Screenings with such assays have indi-
cated that combination of non-structural antigens (NS3 to
NS5) are sufficient to induce protective immunity. A
proof-of-concept study has recently been performed in the
chimpanzee model confirming that a NS-based T-cell vac-
cine can induce non-sterile immunity in 80% of the vac-
cinees [60]. The first vectored vaccine based on three HCV
NS antigens carried by the MVA pox virus strain is entering
the clinics (Transgene).
Mark Wainberg (Jewish General Hospital, McGill Univer-
sity, Montréal, Canada) presented on differences among
HIV-1 subtypes involving the prevalence of the K65R
mutation in reverse transcriptase (RT). This mutation has
principally been identified in the context of tenofovir
usage as part of antiretroviral drug regimens in western
countries, in which subtype B viruses are most predomi-
nant. However, the K65R mutation is seen relatively rarely
in comparison with other substitutions, and, indeed, ten-
ofovir (TDF)-based regimens have been shown to be dura-
ble over long periods, when this drug is used in
association with two other efficient antiviral compounds,
e.g. 3TC and efavirenz. Recently, the Wainberg laboratory
published data showing that selection of the K65R muta-
tion in tissue culture with subtype C viruses under tenofo-
vir pressure led to appearance of the K65R mutation far
more rapidly than occurred with viruses of subtype B ori-
gin. The reasons for this are not well understood, but may
relate to differences, between viruses of subtypes B and C
in coding sequences at amino acid positions 64–66 within
the HIV-1 reverse transcriptase enzyme. More recently,
studies of patients in Botswana, where subtype C viruses
are predominant, who failed antiretroviral therapy based
on use of ddI/d4T/3TC, were shown to have developed
the K65R mutation with relatively high frequency. Thus, it
appears that development of the K65R mutation in sub-
type C viruses may not be specific to the drug utilized but
more to the viral subtype. In brief, subtype C viruses may
have a greater preponderance to develop the K65R muta-
tion than do viruses of subtype B. These findings highlight
the need to monitor for the presence of drug resistance
mutations in settings in which HIV-1 viruses other than
those of subtype B are likely to predominate and to char-
acterize drug resistance mutations associated with differ-
ent viral subtypes [61-63].
Jean-Pierre Routy (Centre Universitaire de Santé McGill,
Montréal, Canada) addressed the important topic of "The
potential for HIV eradication". JP Routy's lecture dealt
with the potential of valproic acid to potentially play a
role in clearing latent HIV infection. The mechanism
whereby this might take place could be through interac-
tion with histone molecules in a way as to provoke
latently infected cells to become overt producers of prog-
eny viruses. This, in turn, might result in their death. JP
Routy explained that differences exist among cells of lym-
phocytic vs monocytic lineage, and that the use of adju-
vant therapies, including valproic acid, as well as that of
various interleukin molecules, needs to be explored in the
context of clinical trials. He explained that different cellu-
lar reservoirs might act in differential fashion when stim-
ulated by chemicals such as valproic acid and/or a variety
of interleukin compounds, such as IL-2, IL-7, and IL-10.
He pointed out that a number of clinical trials to test the
hypothesis that inhibitors of histone deacetylase might
play important roles with respect to provoking expression
of integrated proviral DNA are underway. Conceivably,
the simultaneous use of agents such as valproic acid,
together with effective antiretroviral compounds, could
make a difference in regard to reservoir longevity [64-66].
Host cell editing of nascent retroviral cDNA has been furi-
ously hot topic since Michael Malim's group identified
APOBEC3G as a key molecule restricting HIV DNA repli-Page 5 of 9
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(Institut Pasteur, Paris, France) spoke on mechanistic par-
allels between cytidine and adenosine deamination of
viral nucleic acids. The APOBEC3G enzyme deaminates
multiple cytidine residues to yield uracil residues effec-
tively mutating the genome to death. In experimental set-
tings HBV, HTLV-I and foamy viruses are vulnerable to
editing by this enzyme and others of this 8 gene family. In
vivo editing occurs for HBV and follows up-regulation of
APOBEC3G by type I interferons. While a growth indus-
try, genetic editing of viruses has been known for more
than 20 years. The prototype is adenosine deamination of
double stranded RNA of measles virus by the type I inter-
feron induced ADAR-1L enzyme. Indeed ADAR-1L and
APOBEC3 molecules harbour a highly conserved
HXEXnCXXC motif in the crucial zinc finger. These simi-
larities suggest an ancient gene duplication and evolution
into paralogs with different substrate specificities [68-70].
On the topic of the mechanisms of resistance to antiretro-
viral drugs, Vincent Calvez (Hôpital de la Pitié-Sal-
petrière, Paris, France) discussed the mechanisms of
resistance to HAART that are very complex and important
issues for people living with HIV. As pointed out by V.
Calvez, HIV-1 exemplifies the principles of Darwinian
evolution because of its high replication and mutation
rates. This allows a close look at evolution within periods
of days. Certain selective pressures that drive the evolu-
tion of HIV include chemotherapy, anatomic compart-
mentalization and the immune responses. Resistance to
HAART, and in particular the increasing levels of transmit-
ted resistant viral strains could offset the substantial gains
won with potent antiretroviral therapy. Primary and
acquired antiretroviral resistance rates reflect the relative
usage of different antiretroviral drugs in the population
living with HIV, as well as the inherent genetic barrier to
the development of resistance associated with individual
drugs. Data on antiretroviral resistance rates, gleaned
from the growing HIV-1-infected population treated with
a continuously increasing number of antiretroviral drug
combinations, provide insights into patient management
approaches for delaying the emergence of resistance and
minimizing the degree of resistance. Evolving data suggest
that the relative ease with which HIV-1 escapes the selec-
tive pressure of chronic drug exposure varies for the differ-
ent antiretroviral drug classes and individual
antiretroviral drugs. The development of resistance in vivo
can be anticipated based on these data, in conjunction
with the individual's treatment history and resistance test-
ing results. These in turn can guide clinicians to adapt
HAART treatments and to preserve therapeutic options for
the time when antiretroviral-resistant strains emerge. The
recent developments of new antiretroviral drugs, such as
anti-integrase and boosted protease inhibitors, suggest
that several treatment strategies can limit the develop-
ment of resistance.
Prevention
Julie Bruneau (Centre de Recherche du CHUM, Univer-
sité de Montréal, Canada) focused her presentation on
harm reduction strategies to prevent the transmission of
HIV and HCV among injection drug users. Studies in a
variety of countries provided evidence that Needle
Exchange Programs (NEP) can reduce the incidence of
HIV infection among injection drug users (IDU) [71-75].
In contrast, studies in Montréal and Vancouver attracted
international attention upon reporting an independent
association between NEP attendance and HIV seroconver-
sion [76,77]. These inconsistent findings indicate a need
for more informative assessments of the underlying con-
ditions influencing the impact of NEPs. J. Bruneau pre-
sented a study examining patterns of utilisation of syringe
access programs and geographic proximity to the IDU'
dwelling place, in relation to high-risk syringe sharing
behaviours in a population of IDUs living in Montréal.
Her data confirms that NEPs were implemented in areas
of high IDU density, and demonstrates a positive impact
of a NEP fixed site implemented in such an environment
on HIV prevention. This relationship could be modified,
however, by other attributes of neighbourhoods and is
not as straightforward as suggested by previous reports
[78,79]. In addition, she reported results suggesting that
regardless of the distance, IDUs who consistently acquire
their syringes from the same source are less than half as
likely to report high-risk injection behaviour.
Future pandemics by influenzae viruses
Bruno LINA (HCL, Université de Lyon, France) gave an
overview on new influenza viruses, such as H5N1, as
infectious agents responsible for respiratory tract infec-
tions. For entry human influenza viruses bind sialic acids
(SA) that are linked to glycans via an α2–6 linkage, while
avian influenzae better recognize α2–3 linked SA. This
difference can partly explain why avian viruses do not
infect humans. Until recently, it was postulated that no
α2–3 linked SA were present in man, because the upper
respiratory tract cells harbour only α2–6 linked sialic
acids. The description of H5N1 human cases led to a
closer look at SA linkage in the lower respiratory tract,
showing that ciliated airway and type II alveolar epithelial
cells could display α2–3 linked sialic acids while α2–6 SA
was detected in ciliated and gobelet cells. In the haemag-
glutinin pocket of the receptor-binding site, several amino
acids are key elements of the α2–3 versus α2–6 specificity.
For the well-known 1918 influenza A pandemic strain, it
has been suggested that one single avian to human substi-
tution has been responsible for the adaptation of this
deadly emerging virus. Although the distribution of spe-
cific receptors on target organs and specific amino acidPage 6 of 9
(page number not for citation purposes)
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influenza A viruses, other parameters are controlling
influenza replication in cells. For example, it has been
shown that the replicase complex of the avian viruses is
not efficient in the context of a human cell, because
human cells lack the protein counterparts present in the
avian cell. Therefore, as pointed out by B. Lina, although
necessary for the emergence of influenza pandemic
viruses, the adaptation of the virus to its new receptor is
probably not the only key modification necessary for the
emergence of a new pandemic.
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